{"id":56015,"date":"2023-04-19T19:03:44","date_gmt":"2023-04-19T17:03:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/epic-sciences-announces-medicare-coverage-for-breast-cancer-focused-ctdna-gene-panel\/"},"modified":"2023-04-19T19:03:44","modified_gmt":"2023-04-19T17:03:44","slug":"epic-sciences-announces-medicare-coverage-for-breast-cancer-focused-ctdna-gene-panel","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/epic-sciences-announces-medicare-coverage-for-breast-cancer-focused-ctdna-gene-panel\/","title":{"rendered":"Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel"},"content":{"rendered":"
\n

\nThe 56-gene ctDNA panel is a key component of DefineMBC\u2122, the company\u2019s comprehensive blood biopsy for metastatic breast cancer<\/i><\/p>\n

SAN DIEGO–(BUSINESS WIRE)–Epic Sciences, Inc. announced today that the company\u2019s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region. This panel is a key component of our comprehensive DefineMBC blood biopsy for metastatic breast cancer.<\/p>\n

<\/a><\/p>\n

\nUnder the Medicare coverage policy Epic\u2019s ctDNA panel is covered for Medicare beneficiaries who meet the criteria for coverage which include those patients who have metastatic breast cancer and for whom tissue-based, comprehensive genomic profiling is infeasible. The full list of coverage criteria is available on the MolDX website.<\/p>\n

\n\u201cWe are pleased that Medicare has recognized the clinical value for patients of Epic\u2019s non-invasive ctDNA test, which ultimately will help oncologists make more informed treatment decisions for their patients with metastatic breast cancer,\u201d said Lloyd Sanders, Epic Sciences\u2019 CEO. \u201cWe are working on submitting additional evidence to establish Medicare coverage on the entirety of Epic\u2019s DefineMBC blood biopsy tests so that the full benefit of its comprehensive analysis can be available to patients with metastatic breast cancer.\u201d<\/p>\n

\nThe 56-gene panel was developed to deliver to physicians information about genomic variants that are critical to the management of patients with metastatic breast cancer.<\/p>\n

\nSince the launch of the company\u2019s Clinical Experience Program in April of 2022, DefineMBC test results, including this 56-gene panel, have been delivered to over 700 patients with metastatic breast cancer. Survey results from physicians in the Clinical Experience Program show that 82% found the comprehensive results provided by DefineMBC to be clinically valuable in guiding care, and 88% prefer DefineMBC to more traditional ctDNA-only liquid biopsies.<\/p>\n

\nAbout DefineMBC<\/b><\/p>\n

\nDefineMBC includes both cell-based and cell-free analysis from a single blood draw to provide comprehensive metastatic breast cancer profiling when a tissue biopsy result is not available. The test\u2019s multi-analyte methods have demonstrated sensitivity, specificity, accuracy, and precision in the:<\/p>\n